Microsoft Research

DIA 2024 Global Annual Meeting Welcomes Life Sciences Leaders to Confront Emerging Challenges in Healthcare

Retrieved on: 
Tuesday, April 2, 2024
Medical Devices, FDA, Health, Health Technology, General Health, Pharmaceutical, Eli Lilly, Combination, DCT, Microsoft Research, Artificiality, Trust (social science), GSK, Novartis, Patient, Food and Drug Administration, Artificial intelligence, USS Midway, AI, EMA, Merck & Co., Medicine, European Medicines Agency, Johnson & Johnson, Ecosystem, Drug development, Pharmacovigilance, Food, DIA, Student, Diamond, DEI, Medical device

The ethical use of artificial intelligence (AI) in healthcare, the development of advanced therapies, and other emerging regulatory and scientific challenges demand in-depth discussion as DIA , a global organization of life sciences professionals, accepts registrations for the DIA 2024 Global Annual Meeting , to be held June 16-20 in San Diego.

Key Points: 
  • The ethical use of artificial intelligence (AI) in healthcare, the development of advanced therapies, and other emerging regulatory and scientific challenges demand in-depth discussion as DIA , a global organization of life sciences professionals, accepts registrations for the DIA 2024 Global Annual Meeting , to be held June 16-20 in San Diego.
  • Thousands of industry representatives, regulators, government officials, academics, innovators, and patients will convene for the world's preeminent neutral life sciences forum — and the only thing missing is you.
  • "This year marks the 60th anniversary of DIA and the Global Annual Meeting, and we're celebrating by continuing to forge a bold future marked by innovation and impact," said Marwan Fathallah, DIA's President and Global Chief Executive.
  • — An interactive forum featuring U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) representatives discussing today's regulatory, scientific, and communication challenges.

Volastra Therapeutics Announces New and Expanded Partnerships with AI and Precision-Medicine Leaders to Broaden Potential of KIF18A Inhibitors Across Cancer

Retrieved on: 
Tuesday, March 26, 2024
Software, Research, Pharmaceutical, Oncology, Data Management, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Health, Microsoft, Chromosome, Microsoft Research, Survival, Patient, Biomarker, Nature, Cancer, AI, CIN, Human, Medicine, MBA, FRCP, Therapy, CRISPR, Collaboration, Medical imaging

Volastra leads the field in development of therapeutics that target chromosomal instability (CIN), a key characteristic of cancer associated with accelerated disease progression, increased resistance to therapies, and shortened patient survival.

Key Points: 
  • Volastra leads the field in development of therapeutics that target chromosomal instability (CIN), a key characteristic of cancer associated with accelerated disease progression, increased resistance to therapies, and shortened patient survival.
  • While CIN is a hallmark of cancer, levels of CIN vary widely across tumor types from being nearly ubiquitous in some to only partially present in others.
  • Volastra’s two KIF18A inhibitors are in parallel Phase 1 clinical trials treating tumor types with near-universally high levels of CIN.
  • We are excited to apply our proprietary precision medicine platform to clinical trials in the rapidly advancing field of KIF18A inhibition.”

AI Audits, Equity Awareness in Data Privacy Methods, and Facial Recognition Technologies are Major Topics During This Year’s Privacy Papers for Policymakers Events

Retrieved on: 
Tuesday, April 2, 2024
Transfer, Law school, Artificiality, Public, Facial recognition, University of Groningen, Vrije Universiteit Brussel, LLM, Justice, United States Senate, Safe, Policy, Legislation, FGV, Harm, Microsoft, Employment, Congress, Microsoft Research, Universidad de Montevideo, Risk, Democracy, Facial recognition system, Future, Urban, Legislative assistant, Urban Institute, Privacy, Rochester Institute of Technology, Senate, FPF, ETH Zurich, Forecasting, Internet, Trust (social science), Research, AI, University, Private sector, Personal data, Student, Model, Use, Paper, Information, Element, Algorithm, Upturn, Barnard College, Columbia University, Housing, Government, Salvador Allende, Cryptocurrency

Author: Judy Wang, Communications Intern, FPF The Future of Privacy Forum (FPF) hosted two engaging events honoring 2023’s must-read privacy scholarship at the 14th Annual Privacy Papers for Policymakers ceremonies. On Tuesday, February 27, FPF hosted a Capitol Hill event featuring an opening keynote by U.S. Senator Peter Welch (D-VT) as well as facilitated discussions [?]

Key Points: 


Author: Judy Wang, Communications Intern, FPF The Future of Privacy Forum (FPF) hosted two engaging events honoring 2023’s must-read privacy scholarship at the 14th Annual Privacy Papers for Policymakers ceremonies. On Tuesday, February 27, FPF hosted a Capitol Hill event featuring an opening keynote by U.S. Senator Peter Welch (D-VT) as well as facilitated discussions [?]

Monumo's Anser Engine Achieves Record 10 Million Simulations in 24 Hours

Retrieved on: 
Tuesday, February 27, 2024
Automotive, Vehicle Technology, Environmental Health, Technology, Research, Engineering, Sustainability, Automotive Manufacturing, Manufacturing, Climate Change, Environment, Finance, Green Technology, Professional Services, Other Technology, Performance & Special Interest, Software, EV, Electric Vehicles, Alternative Vehicles, Fuels, Science, SRM, Doctor of Philosophy, Torque, Canadarm, AI, Electronics, Original equipment manufacturer, Physics, Microsoft Research, Arm, Acceleration, Machine learning

The company's scalable, machine learning-friendly, Anser™ Engine is now able to run 10 million simulations in 24 hours.

Key Points: 
  • The company's scalable, machine learning-friendly, Anser™ Engine is now able to run 10 million simulations in 24 hours.
  • This means that we can identify the optimal parameters for specific motor use-cases, whether that is reducing cost, increasing efficiency or improving sustainability.
  • “The Anser Engine has already revealed innovations that surpass human ability, but these incredible results are just the beginning.
  • It’s hard to overstate the role we anticipate this unique combination of technologies will have in the future of engineering disciplines and beyond.”

TalkLife secures new investment from TELUS to improve mental health support

Retrieved on: 
Thursday, February 8, 2024
Partnership, Internet, Growth, Telus Health, Research, TELUS, Networking hardware, University, Microsoft Research, Workplace, SME, Harvard University, University of Washington, Cornell University, Mental health, EAP, MIT, Student

Amid a global mental health crisis, TELUS is exploring new, innovative ways to make mental health support more accessible by partnering with peer support platform TalkLife creating a safe space for people to connect

Key Points: 
  • Amid a global mental health crisis, TELUS is exploring new, innovative ways to make mental health support more accessible by partnering with peer support platform TalkLife creating a safe space for people to connect
    VANCOUVER, BC and BRISTOL, England, Feb. 8, 2024 /PRNewswire/ - UK-based scaleup TalkLife , an innovative global online peer support community for people to talk about their mental health, has secured a capital investment from TELUS Ventures, the investment arm of world-leading communications technology company, TELUS.
  • TalkLife is also a valued partner of TELUS Health , a global healthcare leader supporting over 69 million lives worldwide.
  • "TalkLife is pioneering a new kind of mental health support that's accessible, relevant, and has the research backing to prove that it really works.
  • It will contribute to scale operations, and cement TalkLife's place as the leading peer provider of mental health support globally, helping those who might struggle to access traditional mental health support because of stigma, cost, or availability.

Paige Unveils Game-Changing AI That Revolutionizes Cancer Detection Across Multiple Tissue Types

Retrieved on: 
Monday, January 8, 2024
Radiology, Health Technology, Health, Oncology, Prognosis, FDA, Lung, Doctor of Philosophy, Cancer, Conceptual model, Marie Cassidy, Science, Behavior, Microsoft Research, Preprint, AI1, Library, Gastrointestinal tract, Genomics, DIGITAL, Pathology, ArXiv, Patient, Diagnosis, Rudolf Virchow, Skin, Senior, Medical imaging

Traditionally, development of pathology cancer detection AI applications required large datasets, one tissue type at a time, often taking months or years to build at clinical grade.

Key Points: 
  • Traditionally, development of pathology cancer detection AI applications required large datasets, one tissue type at a time, often taking months or years to build at clinical grade.
  • With data derived from over 4 million digitized slides, Paige's innovative approach removes the constraints of developing single tissue products, making it possible to efficiently create cancer detection AI applications across a multitude of tumor types, a first in AI-based cancer diagnosis.
  • The exceptional performance of Paige’s multi-cancer application across various tissue types is considered state-of-the art in cancer pathology AI1.
  • “We see FDA clearance as being critical to ensure that regulatory and safety standards are being upheld in the application of AI in cancer diagnostics across tumor types,” said Andy Moye, CEO of Paige.

Artificial Intelligence as a Force for Good in the Netherlands

Retrieved on: 
Tuesday, October 10, 2023
Microsoft Research, Multimedia, Innovation Center station, NFIA, Innovation Center for Artificial Intelligence, Netherlands Foreign Investment Agency, Government, AI, Artificial intelligence, Ecosystem, Environment, Research, ICAI, Medical device

WASHINGTON, Oct. 10, 2023 /PRNewswire/ -- The Netherlands is the most wired country in the world and home to an ecosystem of research institutions fostering artificial intelligence (AI) innovation. As a leading AI hub in Europe, the country will host the annual World Summit AI October 11 to 12, 2023 in Amsterdam. The Dutch are digital frontrunners and recognize that AI, fueled by big data, is a driver of opportunity. This event will help spotlight the Netherlands' contributions to AI and Dutch commitment to shaping a future where AI technologies drive progress for societal good. 

Key Points: 
  • This event will help spotlight the Netherlands' contributions to AI and Dutch commitment to shaping a future where AI technologies drive progress for societal good.
  • Amidst the ongoing AI revolution, the Netherlands has emerged as a dynamic incubator for AI development, application and research .
  • Interested in connecting with NFIA during or after the World AI Summit to discuss how the Netherlands could be a good fit for your company?
  • The Netherlands AI Coalition is dedicated to accelerating the pace of AI development in the Netherlands and bringing together AI initiatives.

COSBI and InSilicoTrials Announce Strategic Partnership to Revolutionize Drug Development and Regulatory Approval

Retrieved on: 
Tuesday, June 27, 2023
Computational biology, COSBI, Partnership, Food, Drug development, University, University of Trento, Systems biology, Medicine, Multimedia, Microsoft Research, Artificial intelligence, Ecosystem, Pharmacology, Safety, Medical device

Under this strategic partnership, COSBI will provide InSilicoTrials with its unique computational models and simulation tools, leveraging their expertise in systems biology and computational biology.

Key Points: 
  • Under this strategic partnership, COSBI will provide InSilicoTrials with its unique computational models and simulation tools, leveraging their expertise in systems biology and computational biology.
  • Enrico Domenici, CEO of COSBI, expressed his enthusiasm about the collaboration, stating, "The strategic partnership with InSilicoTrials represents a crucial step toward advancing personalized medicine and nutrition.
  • By integrating our computational models into their simulation platform, we can significantly improve decision-making, reduce costs, and accelerate the regulatory processes involved in drug development."
  • By incorporating COSBI's advanced computational models and simulation tools, we can significantly enhance the efficiency and effectiveness of the drug development and regulatory approval processes."

COSBI and InSilicoTrials Announce Strategic Partnership to Revolutionize Drug Development and Regulatory Approval

Retrieved on: 
Tuesday, June 27, 2023
Computational biology, COSBI, Partnership, Food, Drug development, University, University of Trento, Systems biology, Medicine, Microsoft Research, Artificial intelligence, Ecosystem, Pharmacology, Safety, Medical device

Under this strategic partnership, COSBI will provide InSilicoTrials with its unique computational models and simulation tools, leveraging their expertise in systems biology and computational biology.

Key Points: 
  • Under this strategic partnership, COSBI will provide InSilicoTrials with its unique computational models and simulation tools, leveraging their expertise in systems biology and computational biology.
  • Enrico Domenici, CEO of COSBI, expressed his enthusiasm about the collaboration, stating, "The strategic partnership with InSilicoTrials represents a crucial step toward advancing personalized medicine and nutrition.
  • By integrating our computational models into their simulation platform, we can significantly improve decision-making, reduce costs, and accelerate the regulatory processes involved in drug development."
  • By incorporating COSBI's advanced computational models and simulation tools, we can significantly enhance the efficiency and effectiveness of the drug development and regulatory approval processes."

Top Life Sciences Leaders Assemble for “Illuminate,” the 2023 DIA Global Annual Meeting

Retrieved on: 
Thursday, June 1, 2023
Medical Supplies, Biotechnology, Technology, FDA, Health, General Health, Pharmaceutical, Research, Artificial Intelligence, Science, Clinical Trials, Drug development, ANVISA, Marketing, Policy, COVID-19, WLA, Public policy, Innovation, DCT, Microsoft Research, Future, Patient, Artificial intelligence, Professional development, AI, WHO, Town hall, ChromeOS, Social media, Pharmaceutical industry, Medical device

DIA, the premier professional global community for healthcare product development, will host its 2023 Global Annual Meeting in Boston, June 25-29.

Key Points: 
  • DIA, the premier professional global community for healthcare product development, will host its 2023 Global Annual Meeting in Boston, June 25-29.
  • “The innovative spirit of the 2023 Global Annual Meeting brings together the world’s top scientific minds, industry leaders, regulators, and public policy influencers in one place to share meaningful, revolutionary insights on the challenges that lie ahead.
  • DIA’s 2023 Global Annual Meeting includes over 170 sessions spanning across 13 educational tracks.
  • Learn more about DIA's 2023 Global Annual Meeting by exploring the searchable event program, and by registering for the event here .